Regulus Therapeutics Inc. (NASDAQ:RGLS) Short Interest Down 32.4% in October

Regulus Therapeutics Inc. (NASDAQ:RGLS) was the recipient of a large decline in short interest in October. As of October 31st, there was short interest totalling 1,690,000 shares, a decline of 32.4% from the October 15th total of 2,500,000 shares. Based on an average daily volume of 359,700 shares, the short-interest ratio is currently 4.7 days. Currently, 3.2% of the company’s stock are sold short.

Regulus Therapeutics Price Performance

Shares of Regulus Therapeutics stock traded down $0.07 during trading hours on Friday, hitting $1.43. 261,914 shares of the company’s stock traded hands, compared to its average volume of 1,249,951. The stock has a market capitalization of $93.67 million, a price-to-earnings ratio of -1.34 and a beta of 1.63. Regulus Therapeutics has a 12-month low of $1.08 and a 12-month high of $3.79. The company has a fifty day simple moving average of $1.55 and a 200-day simple moving average of $1.80.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.03). On average, analysts forecast that Regulus Therapeutics will post -0.88 EPS for the current fiscal year.

Hedge Funds Weigh In On Regulus Therapeutics

Institutional investors have recently bought and sold shares of the company. Barclays PLC increased its position in Regulus Therapeutics by 285.2% in the third quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock worth $132,000 after buying an additional 62,549 shares during the last quarter. Jane Street Group LLC bought a new position in shares of Regulus Therapeutics during the 3rd quarter worth $46,000. State Street Corp raised its stake in Regulus Therapeutics by 3.5% in the 3rd quarter. State Street Corp now owns 1,000,998 shares of the biopharmaceutical company’s stock valued at $1,572,000 after acquiring an additional 33,496 shares during the period. Point72 Asset Management L.P. bought a new stake in Regulus Therapeutics in the 3rd quarter valued at about $1,403,000. Finally, NEA Management Company LLC purchased a new stake in Regulus Therapeutics during the third quarter valued at about $10,154,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on RGLS shares. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Regulus Therapeutics in a report on Monday, November 11th. StockNews.com upgraded shares of Regulus Therapeutics to a “sell” rating in a report on Tuesday, September 17th. Finally, Oppenheimer reissued an “outperform” rating and set a $7.00 price target on shares of Regulus Therapeutics in a research report on Wednesday, August 14th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.80.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.